<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04566315</url>
  </required_header>
  <id_info>
    <org_study_id>19-AOIP-04</org_study_id>
    <secondary_id>2020-A01447-32</secondary_id>
    <nct_id>NCT04566315</nct_id>
  </id_info>
  <brief_title>EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT</brief_title>
  <official_title>SYMPTOMATIC EFFECTIVENESS OF MICROPARTICLE ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Centre Hospitalier Universitaire de Nice</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Centre Hospitalier Universitaire de Nice</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The objective of this study is to evaluate at 3 months in a prospective study, the&#xD;
      effectiveness of arterial embolization of neo-vessels in patients with a painful total knee&#xD;
      prosthesis despite a well-conducted medical treatment&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      To date, no study has attempted to measure the effects of arterial embolization on pain in&#xD;
      patients with total knee prosthesis. It would be interesting to evaluate, in a therapeutic&#xD;
      trial with a good level of evidence, this alternative to drug treatments that are often&#xD;
      poorly tolerated, contraindicated or failing in this population of elderly subjects often&#xD;
      presenting co-morbidities. This pilot study will be used to calculate the number of patients&#xD;
      to be included in a comparative, placebo-controlled, double-blind study. In addition to the&#xD;
      evaluation of the undesirable effects of arterial embolization, the objective of this study&#xD;
      is to evaluate the effectiveness at 3 and 6 months of embolization of the neovessels on pain,&#xD;
      stiffness, physical activity, quality of life and consumption of analgesics and&#xD;
      anti-inflammatories.&#xD;
&#xD;
      Evaluation criteria: modification of the pain item in the EVA (Analog Visual Scale), EQ-5D&#xD;
      (quality of life scale), and Knee injury and Osteoarthritis Outcome Score (KOOS)&#xD;
      self-questionnaire collected in the 15 days preceding the procedure and then at 3 and 6&#xD;
      months ; the use of analgesics and anti-inflammatories; adverse events.&#xD;
&#xD;
      Study population: Patients aged 40 to 80 years with a painful total knee joint. The visual&#xD;
      analogue scale (VAS) score must be greater than or equal to 50 mm for at least 3 months&#xD;
      optimal medical treatment, and for whom, no surgical retreatment is indicated.&#xD;
&#xD;
      The expected benefits are the improvement of the treatment of patients in therapeutic&#xD;
      impasse, wearing a total knee prosthesis whose pain is rebellious and disabling. More&#xD;
      generally, the investigators expect an improvement in the quality of life of these patients&#xD;
      currently without satisfactory alternative care.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">October 1, 2020</start_date>
  <completion_date type="Anticipated">April 1, 2022</completion_date>
  <primary_completion_date type="Anticipated">October 1, 2021</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Knee injury self-questionnaire</measure>
    <time_frame>in the 15 days preceding the procedure</time_frame>
    <description>modification of the pain item in the Knee injury self-questionnaire collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Knee injury self-questionnaire</measure>
    <time_frame>at 3 months</time_frame>
    <description>modification of the pain item in the Knee injury self-questionnaire collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoarthritis Outcome Score (KOOS) self-questionnaire</measure>
    <time_frame>in the 15 days preceding the procedure</time_frame>
    <description>and Osteoarthritis Outcome Score (KOOS) self-questionnaire collected</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteoarthritis Outcome Score (KOOS) self-questionnaire</measure>
    <time_frame>at 3 months</time_frame>
    <description>and Osteoarthritis Outcome Score (KOOS) self-questionnaire collected</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>EVA (Analog Visual Scale)</measure>
    <time_frame>in the 15 days preceding the procedure ,</time_frame>
    <description>EVA (Analog Visual Scale) score from 0 to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EVA (Analog Visual Scale)</measure>
    <time_frame>at 3 months</time_frame>
    <description>EVA (Analog Visual Scale) score from 0 to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EVA (Analog Visual Scale)</measure>
    <time_frame>at 6 months</time_frame>
    <description>EVA (Analog Visual Scale) score from 0 to 10</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteoarthritis Outcome Score (KOOS) self-questionnaire</measure>
    <time_frame>in the 15 days preceding the procedure,</time_frame>
    <description>KOOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteoarthritis Outcome Score (KOOS) self-questionnaire</measure>
    <time_frame>at 3 months,</time_frame>
    <description>KOOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Osteoarthritis Outcome Score (KOOS) self-questionnaire</measure>
    <time_frame>at 6 months,</time_frame>
    <description>KOOS</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D (quality of life scale)</measure>
    <time_frame>in the 15 days preceding the procedure</time_frame>
    <description>EQ-5D (quality of life scale)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>EQ-5D (quality of life scale)</measure>
    <time_frame>at 3 months,</time_frame>
    <description>EQ-5D (quality of life scale)</description>
  </secondary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Knee Osteoarthritis</condition>
  <arm_group>
    <arm_group_label>ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>SYMPTOMATIC EFFECTIVENESS OF MICROPARTICLE ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS WITH PAIN RESISTANT TO MEDICAL TREATMENT</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Arteriography knee arteriography</intervention_name>
    <description>arteriography and an injection of inert microparticles of 75 μm in neovessels</description>
    <arm_group_label>ARTERIAL EMBOLIZATION IN PATIENTS WITH TOTAL KNEE PROSTHESIS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Man or woman aged 40 to 80.&#xD;
&#xD;
          -  Total knee joint or bilateral Pain with EVA ≥ 50 mm evolving for at least 3 months&#xD;
             despite the initiation of a well conducted medical treatment according to current&#xD;
             recommendations including analgesics, NSAIDs, rehabilitation and weight loss&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Minor person.&#xD;
&#xD;
          -  Protected adults under the law. Patients deprived of their liberties. Subject not&#xD;
             cooperative or unable to meet the requirements of the protocol.&#xD;
&#xD;
          -  Subject participating in another clinical trial or in period of exclusion from a&#xD;
             previous clinical trial. Severe visceral failure.&#xD;
&#xD;
          -  Local infection. Algoneurodystrophy.&#xD;
&#xD;
          -  Prosthesis loosening.&#xD;
&#xD;
          -  Pregnant or breastfeeding woman.&#xD;
&#xD;
          -  Allergy to contrast media.&#xD;
&#xD;
          -  Chronic or acute renal failure (clearance &lt;30 ml / min).&#xD;
&#xD;
          -  Hemostasis disorders (blood platelet count &lt;50,000 / mm3 or patient TCA / control TCA&gt;&#xD;
             1.2 or TP &lt;50%).&#xD;
&#xD;
          -  Operative indication for removal of the retained prosthesis.&#xD;
&#xD;
          -  Patient with obliterating arterial disease of the lower limbs.&#xD;
&#xD;
          -  Contraindication to lidocaine: Known hypersensitivity to lidocaine hydrochloride, to&#xD;
             local amide anesthetics or to any of the excipients.&#xD;
&#xD;
          -  Patients with recurrent porphyria&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>40 Years</minimum_age>
    <maximum_age>80 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jacques Sedat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Centre Hospitalier Universitaire de Nice</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jacques Sedat, MD</last_name>
    <phone>0492033807</phone>
    <email>sedat.j@chu-nice.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Marion Causeret</last_name>
    <phone>00033492034702</phone>
    <email>causeret.m@chu-nice.fr</email>
  </overall_contact_backup>
  <verification_date>September 2020</verification_date>
  <study_first_submitted>July 24, 2020</study_first_submitted>
  <study_first_submitted_qc>September 22, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">September 28, 2020</study_first_posted>
  <last_update_submitted>September 22, 2020</last_update_submitted>
  <last_update_submitted_qc>September 22, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">September 28, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Osteoarthritis</mesh_term>
    <mesh_term>Osteoarthritis, Knee</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

